Vivosphere
Vivosphere Pre-Clinical is a collaboration between, Microfludyx, SEMPROVA and VivoSphere Inc, incorporating AI-Driven Lab-On-Chip, (AI-OoC) Data Analytics and Reporting Platform to create Pre-Clinical Automated (Robotic )Drug Testing.
AI-OoC more accurately mimicking human responses to various substances, thus potentially reducing the incidence of drug failures during clinical trials.
AI-OoC involves the precise manipulation of fluids at the microscale level, enabling researchers to conduct experiments with minimal sample volumes and high throughput.
By utilizing AI-OoC , our team can obtain more accurate predictions of human responses, to drugs thereby reducing the translational challenges that frequently arise with animal models.
Vivosphere Pre-Clinical AI-OoC platform and services proves invaluable tool in drug discovery.
- Absorption: Utilizing epithelial chips, such as gut-on-a-chip, researchers can study how drugs are absorbed through different bodily barriers, which is vital for oral medications.
- Distribution: These studies investigate how therapeutic compounds distribute within and between different organ systems, influencing efficacy and safety profiles.
- Metabolism: Liver chips are particularly useful for examining how substances are metabolized by the liver, providing insights into potential metabolic pathways and breakdown products.
- Excretion: Understanding how drugs and their metabolites are excreted from the body is crucial for assessing the potential for drug accumulation and resulting toxicity.
- Toxicology (ADME-Tox): Organs-on-chips provide a comprehensive assessment of the absorption, distribution, metabolism, and excretion properties of drugs, alongside their toxicological profiles, ensuring drugs are safe and effective for human use.
